{"id":27086,"date":"2019-07-01T17:08:31","date_gmt":"2019-07-01T15:08:31","guid":{"rendered":"https:\/\/wordpress-783423-2671269.cloudwaysapps.com\/?p=27086"},"modified":"2022-03-14T05:58:55","modified_gmt":"2022-03-14T04:58:55","slug":"01-juli-2019-dermapharm-holding-se-mit-erhoehtem-streubesitz","status":"publish","type":"post","link":"https:\/\/dev.cometis.de\/de\/01-juli-2019-dermapharm-holding-se-mit-erhoehtem-streubesitz\/","title":{"rendered":"01. Juli 2019 | Dermapharm Holding SE mit erh\u00f6htem Streubesitz"},"content":{"rendered":"<p>[et_pb_section fb_built=&#8220;1&#8243; admin_label=&#8220;section&#8220; _builder_version=&#8220;3.22&#8243; global_colors_info=&#8220;{}&#8220; da_is_popup=&#8220;off&#8220; da_exit_intent=&#8220;off&#8220; da_has_close=&#8220;on&#8220; da_alt_close=&#8220;off&#8220; da_dark_close=&#8220;off&#8220; da_not_modal=&#8220;on&#8220; da_is_singular=&#8220;off&#8220; da_with_loader=&#8220;off&#8220; da_has_shadow=&#8220;on&#8220; da_disable_devices=&#8220;off|off|off&#8220;][et_pb_row padding_mobile=&#8220;off&#8220; column_padding_mobile=&#8220;on&#8220; admin_label=&#8220;Zeile&#8220; _builder_version=&#8220;3.25&#8243; background_size=&#8220;initial&#8220; background_position=&#8220;top_left&#8220; background_repeat=&#8220;repeat&#8220; custom_padding=&#8220;||0px|&#8220; make_fullwidth=&#8220;off&#8220; use_custom_width=&#8220;off&#8220; width_unit=&#8220;on&#8220; global_colors_info=&#8220;{}&#8220; column_structure=&#8220;1_2,1_2&#8243;][et_pb_column type=&#8220;1_2&#8243; _builder_version=&#8220;3.25&#8243; custom_padding=&#8220;|||&#8220; global_colors_info=&#8220;{}&#8220; custom_padding__hover=&#8220;|||&#8220;][et_pb_text admin_label=&#8220;Schaltfl\u00e4che %22zur\u00fcck zum Archiv%22&#8243; _builder_version=&#8220;3.27.4&#8243; background_size=&#8220;initial&#8220; background_position=&#8220;top_left&#8220; background_repeat=&#8220;repeat&#8220; text_orientation=&#8220;left&#8220; use_border_color=&#8220;off&#8220; border_color=&#8220;#ffffff&#8220; border_style=&#8220;solid&#8220; global_colors_info=&#8220;{}&#8220;]<\/p>\n<style> .zur\u00fcckbutton:before {display: inline-block; font-family: \"ETmodules\"; content: \"\\4a\"; color: #00225f; margin-right: 7px;} .zur\u00fcckbutton:hover:before {display: inline-block; font-family: \"ETmodules\"; content: \"\\4a\"; color: #d85710; margin-right: 7px;}<\/style>\n<h1>Corporate News<\/h1>\n<p><a class=\"zur\u00fcckbutton\" href=\"https:\/\/dev.cometis.de\/veroeffentlichungsarchiv-dermapharm\">zum Archiv<\/a><br \/>\n[\/et_pb_text][\/et_pb_column][et_pb_column type=&#8220;1_2&#8243; _builder_version=&#8220;3.25&#8243; custom_padding=&#8220;|||&#8220; global_colors_info=&#8220;{}&#8220; custom_padding__hover=&#8220;|||&#8220;][et_pb_image src=&#8220;https:\/\/dev.cometis.de\/wp-content\/uploads\/2018\/08\/autodoc_Logo_Wei%C3%9F_2-7.png&#8220; align=&#8220;right&#8220; align_tablet=&#8220;center&#8220; align_last_edited=&#8220;on|desktop&#8220; admin_label=&#8220;Logo&#8220; _builder_version=&#8220;3.23&#8243; use_border_color=&#8220;off&#8220; border_color=&#8220;#ffffff&#8220; border_style=&#8220;solid&#8220; animation=&#8220;off&#8220; sticky=&#8220;off&#8220; always_center_on_mobile=&#8220;on&#8220; global_colors_info=&#8220;{}&#8220; align_phone=&#8220;center&#8220;][\/et_pb_image][\/et_pb_column][\/et_pb_row][et_pb_row admin_label=&#8220;row&#8220; _builder_version=&#8220;3.25&#8243; background_size=&#8220;initial&#8220; background_position=&#8220;top_left&#8220; background_repeat=&#8220;repeat&#8220; global_colors_info=&#8220;{}&#8220;][et_pb_column type=&#8220;4_4&#8243; _builder_version=&#8220;3.25&#8243; custom_padding=&#8220;|||&#8220; global_colors_info=&#8220;{}&#8220; custom_padding__hover=&#8220;|||&#8220;][et_pb_text admin_label=&#8220;Text&#8220; _builder_version=&#8220;3.27.4&#8243; background_size=&#8220;initial&#8220; background_position=&#8220;top_left&#8220; background_repeat=&#8220;repeat&#8220; text_orientation=&#8220;left&#8220; use_border_color=&#8220;off&#8220; border_color=&#8220;#ffffff&#8220; border_style=&#8220;solid&#8220; saved_tabs=&#8220;all&#8220; global_colors_info=&#8220;{}&#8220;]<\/p>\n<h1>Dermapharm Holding SE mit erh\u00f6htem Streubesitz<\/h1>\n<p><strong>Gr\u00fcnwald, 1. Juli 2019 \u2013 Die Dermapharm Holding SE (\u201eDermapharm\u201c), ein f\u00fchrender Hersteller von patentfreien Markenarzneimitteln f\u00fcr ausgew\u00e4hlte Therapiegebiete in Deutschland mit wachsender internationaler Pr\u00e4senz, wurde von der Themis Beteiligungs-Aktiengesellschaft (\u201eThemis\u201c) dar\u00fcber informiert, dass diese am 28. Juni 2019 580.000 Aktien der Dermapharm zum Preis von 30,00 Euro je Aktie au\u00dferhalb eines Handelsplatzes ver\u00e4u\u00dfert hat. \u00a0<\/strong><\/p>\n<p>Die 580.000 Aktien stammen aus der vereinbarten Greenshoe-Option. Diese Aktien hatte die Themis nach dem B\u00f6rsengang am 9. Februar 2018 zur Stabilisierung des Kurses erworben.<\/p>\n<p>Nach der Ver\u00e4u\u00dferung setzt sich die Aktion\u00e4rsstruktur nun wie folgt zusammen: Mit 75,05\u00a0% (zuvor 76,13\u00a0%) befindet sich die Mehrzahl der St\u00fcckaktien weiterhin im Besitz der Themis. 24,95\u00a0% (zuvor 23,87\u00a0%) der Aktien der Dermapharm liegen im Streubesitz.<\/p>\n<p>Die Dermapharm rechnet damit, dass die Themis bis auf weiteres ihren Anteil an der Dermapharm nicht weiter reduzieren wird.<br \/>\n[\/et_pb_text][et_pb_text admin_label=&#8220;Schaltfl\u00e4che %22Beitrag als PDF%22&#8243; _builder_version=&#8220;3.27.4&#8243; background_size=&#8220;initial&#8220; background_position=&#8220;top_left&#8220; background_repeat=&#8220;repeat&#8220; text_orientation=&#8220;left&#8220; use_border_color=&#8220;off&#8220; border_color=&#8220;#ffffff&#8220; border_style=&#8220;solid&#8220; global_colors_info=&#8220;{}&#8220;]<\/p>\n<div class=\"leseprobe-archiv\"><a title=\"Beitrag als PDF\" href=\"https:\/\/dev.cometis.de\/wp-content\/uploads\/2019\/07\/d_190701_CN_directorsdealings_FINAL.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Beitrag als PDF<\/a><\/div>\n<style> .leseprobe-archiv {color: #00225f !important; border-color: #00225f; position: relative; padding: 0.3em 1em; border: 1px solid; -webkit-border-radius: 3px; -moz-border-radius: 3px; border-radius: 3px; -webkit-transition: all 0.2s; -moz-transition: all 0.2s; transition: all 0.2s; padding:10px; width: 19%; text-align: center; margin-right: 10px; float:left;} .leseprobe-archiv:hover {background-color: #eee; border-color: #ffffff; cursor: pointer;}<\/style>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Gr\u00fcnwald, 1. Juli 2019 \u2013 Die Dermapharm Holding SE (\u201eDermapharm\u201c), ein f\u00fchrender Hersteller von patentfreien Markenarzneimitteln f\u00fcr ausgew\u00e4hlte Therapiegebiete in Deutschland mit wachsender internationaler Pr\u00e4senz, wurde von der Themis Beteiligungs-Aktiengesellschaft (\u201eThemis\u201c) dar\u00fcber informiert, dass diese am 28. Juni 2019 580.000 Aktien der Dermapharm zum Preis von 30,00 Euro je Aktie au\u00dferhalb eines Handelsplatzes ver\u00e4u\u00dfert hat.<\/p>\n","protected":false},"author":24813,"featured_media":54373,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_et_pb_use_builder":"on","_et_pb_old_content":"","_et_gb_content_width":"","inline_featured_image":false,"footnotes":""},"categories":[260,447],"tags":[497],"class_list":["post-27086","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-dermapharm-corporate-news","category-news","tag-497"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v24.5 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>01. Juli 2019 | Dermapharm Holding SE mit erh\u00f6htem Streubesitz - cometis AG<\/title>\n<meta name=\"robots\" content=\"noindex, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<meta property=\"og:locale\" content=\"de_DE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"01. Juli 2019 | Dermapharm Holding SE mit erh\u00f6htem Streubesitz - cometis AG\" \/>\n<meta property=\"og:description\" content=\"Gr\u00fcnwald, 1. Juli 2019 \u2013 Die Dermapharm Holding SE (\u201eDermapharm\u201c), ein f\u00fchrender Hersteller von patentfreien Markenarzneimitteln f\u00fcr ausgew\u00e4hlte Therapiegebiete in Deutschland mit wachsender internationaler Pr\u00e4senz, wurde von der Themis Beteiligungs-Aktiengesellschaft (\u201eThemis\u201c) dar\u00fcber informiert, dass diese am 28. Juni 2019 580.000 Aktien der Dermapharm zum Preis von 30,00 Euro je Aktie au\u00dferhalb eines Handelsplatzes ver\u00e4u\u00dfert hat.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/dev.cometis.de\/de\/01-juli-2019-dermapharm-holding-se-mit-erhoehtem-streubesitz\/\" \/>\n<meta property=\"og:site_name\" content=\"cometis AG\" \/>\n<meta property=\"article:published_time\" content=\"2019-07-01T15:08:31+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2022-03-14T04:58:55+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/dev.cometis.de\/wp-content\/uploads\/2022\/03\/icon_newsroom.svg\" \/>\n\t<meta property=\"og:image:width\" content=\"1\" \/>\n\t<meta property=\"og:image:height\" content=\"1\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Assistenz cometis AG\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Verfasst von\" \/>\n\t<meta name=\"twitter:data1\" content=\"Assistenz cometis AG\" \/>\n\t<meta name=\"twitter:label2\" content=\"Gesch\u00e4tzte Lesezeit\" \/>\n\t<meta name=\"twitter:data2\" content=\"3\u00a0Minuten\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/dev.cometis.de\/de\/01-juli-2019-dermapharm-holding-se-mit-erhoehtem-streubesitz\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/dev.cometis.de\/de\/01-juli-2019-dermapharm-holding-se-mit-erhoehtem-streubesitz\/\"},\"author\":{\"name\":\"Assistenz cometis AG\",\"@id\":\"https:\/\/dev.cometis.de\/de\/#\/schema\/person\/6790c5b0cf28f5e8c09401346770e6f6\"},\"headline\":\"01. Juli 2019 | Dermapharm Holding SE mit erh\u00f6htem Streubesitz\",\"datePublished\":\"2019-07-01T15:08:31+00:00\",\"dateModified\":\"2022-03-14T04:58:55+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/dev.cometis.de\/de\/01-juli-2019-dermapharm-holding-se-mit-erhoehtem-streubesitz\/\"},\"wordCount\":519,\"publisher\":{\"@id\":\"https:\/\/dev.cometis.de\/de\/#organization\"},\"image\":{\"@id\":\"https:\/\/dev.cometis.de\/de\/01-juli-2019-dermapharm-holding-se-mit-erhoehtem-streubesitz\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/dev.cometis.de\/wp-content\/uploads\/2022\/03\/icon_newsroom.svg\",\"keywords\":[\"2019\"],\"articleSection\":[\"Dermapharm Corporate News\",\"News\"],\"inLanguage\":\"de\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/dev.cometis.de\/de\/01-juli-2019-dermapharm-holding-se-mit-erhoehtem-streubesitz\/\",\"url\":\"https:\/\/dev.cometis.de\/de\/01-juli-2019-dermapharm-holding-se-mit-erhoehtem-streubesitz\/\",\"name\":\"01. Juli 2019 | Dermapharm Holding SE mit erh\u00f6htem Streubesitz - cometis AG\",\"isPartOf\":{\"@id\":\"https:\/\/dev.cometis.de\/de\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/dev.cometis.de\/de\/01-juli-2019-dermapharm-holding-se-mit-erhoehtem-streubesitz\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/dev.cometis.de\/de\/01-juli-2019-dermapharm-holding-se-mit-erhoehtem-streubesitz\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/dev.cometis.de\/wp-content\/uploads\/2022\/03\/icon_newsroom.svg\",\"datePublished\":\"2019-07-01T15:08:31+00:00\",\"dateModified\":\"2022-03-14T04:58:55+00:00\",\"inLanguage\":\"de\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/dev.cometis.de\/de\/01-juli-2019-dermapharm-holding-se-mit-erhoehtem-streubesitz\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"de\",\"@id\":\"https:\/\/dev.cometis.de\/de\/01-juli-2019-dermapharm-holding-se-mit-erhoehtem-streubesitz\/#primaryimage\",\"url\":\"https:\/\/dev.cometis.de\/wp-content\/uploads\/2022\/03\/icon_newsroom.svg\",\"contentUrl\":\"https:\/\/dev.cometis.de\/wp-content\/uploads\/2022\/03\/icon_newsroom.svg\",\"caption\":\"Icon Newsroom_news\"},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/dev.cometis.de\/de\/#website\",\"url\":\"https:\/\/dev.cometis.de\/de\/\",\"name\":\"cometis AG\",\"description\":\"Deutschlands f\u00fchrende Investor Relations Agentur\",\"publisher\":{\"@id\":\"https:\/\/dev.cometis.de\/de\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/dev.cometis.de\/de\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"de\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/dev.cometis.de\/de\/#organization\",\"name\":\"cometis AG\",\"alternateName\":\"Deutschlands f\u00fchrende Investor Relations Agentur\",\"url\":\"https:\/\/dev.cometis.de\/de\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"de\",\"@id\":\"https:\/\/dev.cometis.de\/de\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/dev.cometis.de\/wp-content\/uploads\/2022\/01\/Cometis-Mobile-Logo-1.png\",\"contentUrl\":\"https:\/\/dev.cometis.de\/wp-content\/uploads\/2022\/01\/Cometis-Mobile-Logo-1.png\",\"width\":171,\"height\":31,\"caption\":\"cometis AG\"},\"image\":{\"@id\":\"https:\/\/dev.cometis.de\/de\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/dev.cometis.de\/de\/#\/schema\/person\/6790c5b0cf28f5e8c09401346770e6f6\",\"name\":\"Assistenz cometis AG\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"de\",\"@id\":\"https:\/\/dev.cometis.de\/de\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/d9db77bcddbfa0c99848135c21ae5b93?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/d9db77bcddbfa0c99848135c21ae5b93?s=96&d=mm&r=g\",\"caption\":\"Assistenz cometis AG\"},\"url\":\"https:\/\/dev.cometis.de\/de\/author\/assistenz-cometis-ag\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"01. Juli 2019 | Dermapharm Holding SE mit erh\u00f6htem Streubesitz - cometis AG","robots":{"index":"noindex","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"og_locale":"de_DE","og_type":"article","og_title":"01. Juli 2019 | Dermapharm Holding SE mit erh\u00f6htem Streubesitz - cometis AG","og_description":"Gr\u00fcnwald, 1. Juli 2019 \u2013 Die Dermapharm Holding SE (\u201eDermapharm\u201c), ein f\u00fchrender Hersteller von patentfreien Markenarzneimitteln f\u00fcr ausgew\u00e4hlte Therapiegebiete in Deutschland mit wachsender internationaler Pr\u00e4senz, wurde von der Themis Beteiligungs-Aktiengesellschaft (\u201eThemis\u201c) dar\u00fcber informiert, dass diese am 28. Juni 2019 580.000 Aktien der Dermapharm zum Preis von 30,00 Euro je Aktie au\u00dferhalb eines Handelsplatzes ver\u00e4u\u00dfert hat.","og_url":"https:\/\/dev.cometis.de\/de\/01-juli-2019-dermapharm-holding-se-mit-erhoehtem-streubesitz\/","og_site_name":"cometis AG","article_published_time":"2019-07-01T15:08:31+00:00","article_modified_time":"2022-03-14T04:58:55+00:00","og_image":[{"url":"https:\/\/dev.cometis.de\/wp-content\/uploads\/2022\/03\/icon_newsroom.svg","width":1,"height":1,"type":"image\/png"}],"author":"Assistenz cometis AG","twitter_card":"summary_large_image","twitter_misc":{"Verfasst von":"Assistenz cometis AG","Gesch\u00e4tzte Lesezeit":"3\u00a0Minuten"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/dev.cometis.de\/de\/01-juli-2019-dermapharm-holding-se-mit-erhoehtem-streubesitz\/#article","isPartOf":{"@id":"https:\/\/dev.cometis.de\/de\/01-juli-2019-dermapharm-holding-se-mit-erhoehtem-streubesitz\/"},"author":{"name":"Assistenz cometis AG","@id":"https:\/\/dev.cometis.de\/de\/#\/schema\/person\/6790c5b0cf28f5e8c09401346770e6f6"},"headline":"01. Juli 2019 | Dermapharm Holding SE mit erh\u00f6htem Streubesitz","datePublished":"2019-07-01T15:08:31+00:00","dateModified":"2022-03-14T04:58:55+00:00","mainEntityOfPage":{"@id":"https:\/\/dev.cometis.de\/de\/01-juli-2019-dermapharm-holding-se-mit-erhoehtem-streubesitz\/"},"wordCount":519,"publisher":{"@id":"https:\/\/dev.cometis.de\/de\/#organization"},"image":{"@id":"https:\/\/dev.cometis.de\/de\/01-juli-2019-dermapharm-holding-se-mit-erhoehtem-streubesitz\/#primaryimage"},"thumbnailUrl":"https:\/\/dev.cometis.de\/wp-content\/uploads\/2022\/03\/icon_newsroom.svg","keywords":["2019"],"articleSection":["Dermapharm Corporate News","News"],"inLanguage":"de"},{"@type":"WebPage","@id":"https:\/\/dev.cometis.de\/de\/01-juli-2019-dermapharm-holding-se-mit-erhoehtem-streubesitz\/","url":"https:\/\/dev.cometis.de\/de\/01-juli-2019-dermapharm-holding-se-mit-erhoehtem-streubesitz\/","name":"01. Juli 2019 | Dermapharm Holding SE mit erh\u00f6htem Streubesitz - cometis AG","isPartOf":{"@id":"https:\/\/dev.cometis.de\/de\/#website"},"primaryImageOfPage":{"@id":"https:\/\/dev.cometis.de\/de\/01-juli-2019-dermapharm-holding-se-mit-erhoehtem-streubesitz\/#primaryimage"},"image":{"@id":"https:\/\/dev.cometis.de\/de\/01-juli-2019-dermapharm-holding-se-mit-erhoehtem-streubesitz\/#primaryimage"},"thumbnailUrl":"https:\/\/dev.cometis.de\/wp-content\/uploads\/2022\/03\/icon_newsroom.svg","datePublished":"2019-07-01T15:08:31+00:00","dateModified":"2022-03-14T04:58:55+00:00","inLanguage":"de","potentialAction":[{"@type":"ReadAction","target":["https:\/\/dev.cometis.de\/de\/01-juli-2019-dermapharm-holding-se-mit-erhoehtem-streubesitz\/"]}]},{"@type":"ImageObject","inLanguage":"de","@id":"https:\/\/dev.cometis.de\/de\/01-juli-2019-dermapharm-holding-se-mit-erhoehtem-streubesitz\/#primaryimage","url":"https:\/\/dev.cometis.de\/wp-content\/uploads\/2022\/03\/icon_newsroom.svg","contentUrl":"https:\/\/dev.cometis.de\/wp-content\/uploads\/2022\/03\/icon_newsroom.svg","caption":"Icon Newsroom_news"},{"@type":"WebSite","@id":"https:\/\/dev.cometis.de\/de\/#website","url":"https:\/\/dev.cometis.de\/de\/","name":"cometis AG","description":"Deutschlands f\u00fchrende Investor Relations Agentur","publisher":{"@id":"https:\/\/dev.cometis.de\/de\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/dev.cometis.de\/de\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"de"},{"@type":"Organization","@id":"https:\/\/dev.cometis.de\/de\/#organization","name":"cometis AG","alternateName":"Deutschlands f\u00fchrende Investor Relations Agentur","url":"https:\/\/dev.cometis.de\/de\/","logo":{"@type":"ImageObject","inLanguage":"de","@id":"https:\/\/dev.cometis.de\/de\/#\/schema\/logo\/image\/","url":"https:\/\/dev.cometis.de\/wp-content\/uploads\/2022\/01\/Cometis-Mobile-Logo-1.png","contentUrl":"https:\/\/dev.cometis.de\/wp-content\/uploads\/2022\/01\/Cometis-Mobile-Logo-1.png","width":171,"height":31,"caption":"cometis AG"},"image":{"@id":"https:\/\/dev.cometis.de\/de\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/dev.cometis.de\/de\/#\/schema\/person\/6790c5b0cf28f5e8c09401346770e6f6","name":"Assistenz cometis AG","image":{"@type":"ImageObject","inLanguage":"de","@id":"https:\/\/dev.cometis.de\/de\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/d9db77bcddbfa0c99848135c21ae5b93?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/d9db77bcddbfa0c99848135c21ae5b93?s=96&d=mm&r=g","caption":"Assistenz cometis AG"},"url":"https:\/\/dev.cometis.de\/de\/author\/assistenz-cometis-ag\/"}]}},"_links":{"self":[{"href":"https:\/\/dev.cometis.de\/de\/wp-json\/wp\/v2\/posts\/27086","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/dev.cometis.de\/de\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/dev.cometis.de\/de\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/dev.cometis.de\/de\/wp-json\/wp\/v2\/users\/24813"}],"replies":[{"embeddable":true,"href":"https:\/\/dev.cometis.de\/de\/wp-json\/wp\/v2\/comments?post=27086"}],"version-history":[{"count":2,"href":"https:\/\/dev.cometis.de\/de\/wp-json\/wp\/v2\/posts\/27086\/revisions"}],"predecessor-version":[{"id":56368,"href":"https:\/\/dev.cometis.de\/de\/wp-json\/wp\/v2\/posts\/27086\/revisions\/56368"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/dev.cometis.de\/de\/wp-json\/wp\/v2\/media\/54373"}],"wp:attachment":[{"href":"https:\/\/dev.cometis.de\/de\/wp-json\/wp\/v2\/media?parent=27086"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/dev.cometis.de\/de\/wp-json\/wp\/v2\/categories?post=27086"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/dev.cometis.de\/de\/wp-json\/wp\/v2\/tags?post=27086"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}